Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387361461> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4387361461 abstract "Abstract Disclosure: C. Kang: None. J. Oh: None. E. Wang: None. S. Lee: None. J. Nam: None. J. Hong: None. E. Lee: None. C. Ku: None. Background: Rosiglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPAR γ) ligand, are used to treat type II diabetes. Over the last few years, PPAR γ has received much attention for its ability to exert variable tumors. Objective: The aim of this study is to investigate the anti-tumor effect of rosiglitazone on prolactin secreting pituitary adenomas and its mechanism. Materials & Methods: Lactotroph cell line (GH4, MMQ) were treated with Phosphate-buffered saline (PBS) or rosiglitazone. In vitro analysis such as qPCR, immunoblot, prolactin (PRL) ELISA, Cell proliferation assay, and Fluorescence-activating cell sorting (FACS) analysis were performed to examine the effect of rosiglitazone on Lactotroph cell lines. Result: To investigate the direct effect of rosiglitazone on PRL secretion of the pituitary adenomas, GH4 and MMQ cells were treated with rosiglitazone 1, 5, 10, 50 μM for 72 hr. Both PRL mRNA and secretion levels were significantly decreased by rosiglitazone in a dose-dependent manner. In previous studies, 15-PDGH has been implicated as a tumor suppressor gene with the property that inhibits the tumor growth. Interestingly, 5 μM rosiglitazone upregulated the mRNA and protein levels of 15-PDGH in both GH4 (4.73-fold) and MMQ (4.04-fold) cells. Next, we investigated whether rosiglitazone had any effects on the proliferation of prolactinoma cells. Proliferation of the GH4 and MMQ cells were significantly decreased by rosiglitazone in a dose-dependent manner after treatment. Rosiglitazone potently induced cell cycle arrest in sub-G1inGH4 and MMQ cells. Furthermore, rosiglitazone treatment significantly increased both early (2.31-fold) and late apoptosis (1.9-fold) of GH4 and MMQ cells. Conclusion: These results collectively position 15-PDGH as a potential new therapeutic target for prolactinomas and implicate rosiglitazone as a possible alternative pharmacological approach for prolactinomas. Presentation: Thursday, June 15, 2023" @default.
- W4387361461 created "2023-10-06" @default.
- W4387361461 creator A5037297905 @default.
- W4387361461 creator A5041025105 @default.
- W4387361461 creator A5050505435 @default.
- W4387361461 creator A5057670291 @default.
- W4387361461 creator A5059898659 @default.
- W4387361461 creator A5067769159 @default.
- W4387361461 creator A5077800857 @default.
- W4387361461 date "2023-10-01" @default.
- W4387361461 modified "2023-10-06" @default.
- W4387361461 title "THU553 Anti-tumor Effect Of Rosiglitazone Via Upregulating 15-PDGH In Prolactin Secreting Adenoma" @default.
- W4387361461 doi "https://doi.org/10.1210/jendso/bvad114.2179" @default.
- W4387361461 hasPublicationYear "2023" @default.
- W4387361461 type Work @default.
- W4387361461 citedByCount "0" @default.
- W4387361461 crossrefType "journal-article" @default.
- W4387361461 hasAuthorship W4387361461A5037297905 @default.
- W4387361461 hasAuthorship W4387361461A5041025105 @default.
- W4387361461 hasAuthorship W4387361461A5050505435 @default.
- W4387361461 hasAuthorship W4387361461A5057670291 @default.
- W4387361461 hasAuthorship W4387361461A5059898659 @default.
- W4387361461 hasAuthorship W4387361461A5067769159 @default.
- W4387361461 hasAuthorship W4387361461A5077800857 @default.
- W4387361461 hasBestOaLocation W43873614611 @default.
- W4387361461 hasConcept C104317684 @default.
- W4387361461 hasConcept C126322002 @default.
- W4387361461 hasConcept C127561419 @default.
- W4387361461 hasConcept C134018914 @default.
- W4387361461 hasConcept C170493617 @default.
- W4387361461 hasConcept C185592680 @default.
- W4387361461 hasConcept C2778918492 @default.
- W4387361461 hasConcept C2779064019 @default.
- W4387361461 hasConcept C2780152017 @default.
- W4387361461 hasConcept C54799321 @default.
- W4387361461 hasConcept C55493867 @default.
- W4387361461 hasConcept C62112901 @default.
- W4387361461 hasConcept C71315377 @default.
- W4387361461 hasConcept C71924100 @default.
- W4387361461 hasConceptScore W4387361461C104317684 @default.
- W4387361461 hasConceptScore W4387361461C126322002 @default.
- W4387361461 hasConceptScore W4387361461C127561419 @default.
- W4387361461 hasConceptScore W4387361461C134018914 @default.
- W4387361461 hasConceptScore W4387361461C170493617 @default.
- W4387361461 hasConceptScore W4387361461C185592680 @default.
- W4387361461 hasConceptScore W4387361461C2778918492 @default.
- W4387361461 hasConceptScore W4387361461C2779064019 @default.
- W4387361461 hasConceptScore W4387361461C2780152017 @default.
- W4387361461 hasConceptScore W4387361461C54799321 @default.
- W4387361461 hasConceptScore W4387361461C55493867 @default.
- W4387361461 hasConceptScore W4387361461C62112901 @default.
- W4387361461 hasConceptScore W4387361461C71315377 @default.
- W4387361461 hasConceptScore W4387361461C71924100 @default.
- W4387361461 hasIssue "Supplement_1" @default.
- W4387361461 hasLocation W43873614611 @default.
- W4387361461 hasOpenAccess W4387361461 @default.
- W4387361461 hasPrimaryLocation W43873614611 @default.
- W4387361461 hasRelatedWork W1983820617 @default.
- W4387361461 hasRelatedWork W1987346504 @default.
- W4387361461 hasRelatedWork W1991236884 @default.
- W4387361461 hasRelatedWork W1999782614 @default.
- W4387361461 hasRelatedWork W2000649392 @default.
- W4387361461 hasRelatedWork W2020486366 @default.
- W4387361461 hasRelatedWork W2024593790 @default.
- W4387361461 hasRelatedWork W2047011646 @default.
- W4387361461 hasRelatedWork W2047320607 @default.
- W4387361461 hasRelatedWork W4281726954 @default.
- W4387361461 hasVolume "7" @default.
- W4387361461 isParatext "false" @default.
- W4387361461 isRetracted "false" @default.
- W4387361461 workType "article" @default.